The Mental Health Watchdog calls for reforms to protect public safety, citing decades of antidepressant, electroshock, and psychedelic drug risks.

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

Report Ocean has published a new report on the Narcolepsy Therapeutics Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers ...

Many types of medications, including over-the-counter (OTC) and prescription drugs, can help relieve joint pain due to ...

Selective serotonin reuptake inhibitors have relatively few side effects. They're also usually better tolerated than other types of antidepressants like serotonin and norepinephrine reuptake ...

This effect has not been attributed to antidepressants other than SSRIs. [57] The ENRICHD trial did not provide the definitive answers hoped for concerning whether treating depression and LPSS ...

Thousands of bottles of an antidepressant have been recalled by the U.S. Food and Drug Administration due to a cancer-causing chemical. The voluntary recall for 7,107 bottles of the generic form ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Over 7,000 bottles of the antidepressant medication ...

Earlier this week, the U.S. Food and Drug Administration announced a significant recall of over 7,100 bottles of duloxetine, a generic form of the popular antidepressant Cymbalta. The recall was ...

The U.S. Food and Drug Administration announced a Class II recall for more than 7,100 bottles of Duloxetine — a generic antidepressant for Cymbalta — due to a cancerous chemical. A voluntary ...

The U.S. Food and Drug Administration announced a Class II recall for more than 7,100 bottles of Duloxetine — a generic antidepressant for Cymbalta — due to a cancerous chemical. A voluntary ...

The Food and Drug Administration (FDA) has issued a Class II recall for over 7,000 bottles of duloxetine, a popular antidepressant, due to the presence of a potentially carcinogenic chemical.